Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia [1]

International Journal of Hematology

Volumn 75, Issue 1, 2002, Pages 104-106

  Mikoshiba, Michiaki ^a   Ohashi, Kazuteru ^a   Takei, Naoko ^a   Okuyama, Yoshiki ^a   Maeda, Yasuharu ^a   Hiruma, Kiyoshi ^a   Akiyama, Hideki ^a   Fukuhara, Osamu ^b   Takeshita, Akihiro ^c   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Department of Internal Medicine   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID; TAMIBAROTENE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ANAMNESIS; BLEEDING TENDENCY; BONE MARROW TRANSPLANTATION; CASE REPORT; CHEMOTHERAPY; FEMALE; HUMAN; LETTER; PANCYTOPENIA; PROMYELOCYTIC LEUKEMIA; RELAPSE; ALLOTRANSPLANTATION; DRUG RESISTANCE; IMMUNOSUPPRESSIVE TREATMENT; MULTIMODALITY CANCER THERAPY; REMISSION; SALVAGE THERAPY;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036363221     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02981989     Document Type: Letter

References (12)

1. Hozumi M. Differentiation therapy of leukemia: achievements, limitations and future prospects. Int J Hematol. 1998;68(2):107-129.
2. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90:967-973.
3. Niu C, Yan H, Sun HP, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324.
4. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
5. Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia. Br J Haematol. 1998;103:1092-1095.
6. Westervelt P, Brown RA, Douglas RA, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98:266-271.
7. 3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345-3353.
8. 3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
9. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001;6(suppl 2):11-16.
10. Galimberti S, Papineschi F, Carmignani A, et al. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant. 1999;24:345-348.
11. Asou N, Adachi K, Tamura J, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 1997;40(suppl): S30-S35.
12. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of prophylactic ursodeoxycholic acid for veno-occlusive disease of the liver in patients undergoing stem cell transplantation. Am J Hematol. 2000;64:32-38.